Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase NA 2Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 22Colorectal Neoplasms 14Ovarian Neoplasms 12Lung Neoplasms 10Neoplasm Metastasis 9Stomach Neoplasms 8Neoplasms 8Nasopharyngeal Carcinoma 8Leukemia, Myeloid, Acute 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Rectal Neoplasms 6Fallopian Tube Neoplasms 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Esophageal Squamous Cell Carcinoma 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Lymphoma, Non-Hodgkin 4Leukemia 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Carcinoma, Ovarian Epithelial 4Pancreatic Neoplasms 3Neoplasms by Site 3Lymphoma, Large B-Cell, Diffuse 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Multiple Myeloma 2

Interventions

Cyclophosphamide 60Vincristine 57Doxorubicin 54Rituximab 48Prednisone 44Etoposide 35Radiotherapy 34Cytarabine 26Filgrastim 22Methotrexate 21Bleomycin 21Dexamethasone 18Peripheral Blood Stem Cell Transplantation 14Carmustine 14Vinblastine 13Prednisolone 13VAP-cyclo protocol 12Melphalan 12Mitoxantrone 11Mercaptopurine 10Leucovorin 10Dacarbazine 9Ifosfamide 8Granulocyte Colony-Stimulating Factor 8Procarbazine 7Methylprednisolone 7Lenalidomide 7Gemcitabine 7Daunorubicin 7Cisplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma × Drug Therapy × Clear all
NCT00004112 2024-09-23

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

University of Nebraska

Phase 3 Completed
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡